NCT01358968View on ClinicalTrials.gov

A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2012

Conditions
Cancer
Interventions
DRUG

LY2603618

Administered intravenously as a 1-hour infusion.

DRUG

Desipramine

Administered orally

DRUG

Pemetrexed

Administered intravenously as a 10-minute infusion.

DRUG

Gemcitabine

Administered intravenously as a 30-minute infusion.

Trial Locations (1)

38120

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01358968 - A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine | Biotech Hunter | Biotech Hunter